Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Sean Bohen will present at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Sean Bohen will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 2:15 p.m. PT. The presentation will be available via a live webcast on Olema's Investor Relations website and archived for at least 30 days. Olema focuses on targeted therapies for women's cancers, with its lead candidate, OP-1250, currently in Phase 2 trials and granted FDA Fast Track designation. The company is headquartered in San Francisco.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was +7.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET).
A live webcast of the presentation and any accompanying presentation materials will be available under the News & Events section of Olema’s Investor Relations website at www.olema.com. The webcast will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
IR Contact:
Courtney Dugan, Vice President, Investor Relations and Communications
ir@olema.com
Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.